In the BioHarmony Drug Report Database

"Preview" Icon

Mafodotin

Blenrep (mafodotin) is a small molecule pharmaceutical. Mafodotin was first approved as Blenrep on 2020-08-25. It has been approved in Europe to treat multiple myeloma. It is known to target tumor necrosis factor receptor superfamily member 17.

 

Trade Name

 

Blenrep
 

Common Name

 

mafodotin
 

ChEMBL ID

 

CHEMBL2107813
 

Indication

 

multiple myeloma
 

Drug Class

 

Synthetic analogs of the dolastatin series

Image (chem structure or protein)

Mafodotin structure rendering